{"meshTags":["Protein Kinase Inhibitors","Clinical Trials, Phase III as Topic","Receptor, Epidermal Growth Factor","Humans","Quinazolines","Antineoplastic Agents","Esophageal Neoplasms"],"meshMinor":["Protein Kinase Inhibitors","Clinical Trials, Phase III as Topic","Receptor, Epidermal Growth Factor","Humans","Quinazolines","Antineoplastic Agents","Esophageal Neoplasms"],"genes":["EGFR","EGFR"],"publicationTypes":["News"],"abstract":"Findings from the phase III TRANS-COG clinical trial suggest that the EGFR inhibitor gefitinib may extend overall survival in patients with esophageal cancer whose tumors have extra copies of EGFR. ","title":"Gefitinib extends survival in some esophageal cancers.","pubmedId":"25583816"}